Acute excisional wounds treated with a tissue-engineered skin (Apligraf)

Dermatol Surg. 1999 Mar;25(3):195-201. doi: 10.1046/j.1524-4725.1999.08186.x.

Abstract

Background: Tissue-engineered products are usually composed of living cells and their supporting matrices that have been grown in vitro, using a combination of engineering and life sciences principles. Apligraf is a bilayered product composed of neonatal-derived dermal fibroblasts and keratinocytes, and Type I bovine collagen.

Objective: To evaluate in a prospective, multicentered open study, the effects of tissue therapy with a tissue-engineered skin (Apligraf) with partial or full-thickness excisional wounds.

Methods: One hundred and seven patients participated in this study. The tissue-engineered skin was applied once, immediately after excisional surgery, usually for skin cancer, and patients were followed for up to one year.

Results: The safety results were impressive, with no clinical or laboratory evidence of rejection. Clinically, graft persistence was good to excellent in 77 of 105 (73.3%) of patients at one week, falling to 56.6% and 53.6% at two weeks and one month respectively.

Conclusion: To date, this is the largest experience with a tissue-engineered skin product in acute wounds, and this study suggests that tissue therapy may be safe and useful.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / analysis
  • Cattle
  • Collagen / immunology
  • Collagen / therapeutic use
  • Dermatologic Surgical Procedures*
  • Fibroblasts
  • Graft Rejection
  • Humans
  • Keratinocytes
  • Prospective Studies
  • Reconstructive Surgical Procedures*
  • Reoperation
  • Skin Neoplasms / surgery
  • Skin Pigmentation
  • Skin, Artificial* / adverse effects
  • Treatment Outcome

Substances

  • Antibodies
  • Collagen